این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Journal of Pharmaceutical Care، جلد ۹، شماره ۳، صفحات ۱۲۹-۱۳۶
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Efficacy and Safety of Interferon Beta-1b in the Management of Patients with COVID-19: A Prospective, Open-Label, Non-Randomized Trial
چکیده انگلیسی مقاله Backgrounds: There is no proven therapy for coronavirus disease 2019 (COVID-19) so far. The aim of this study was to evaluate the effect of interferon beta-1b combined with lopinavir/ritonavir and hydroxychloroquine in managing COVID-19.Methods: This is a non-randomized, open-label study on adult patients with moderate to severe COVID-19. The patients (≥ 18 years) received hydroxychloroquine 400 mg single dose, and lopinavir 400 mg/ritonavir 100 mg every 12 h (for 7-10 days) with or without subcutaneous interferon (IFN) beta-1b 250 mcg every other day for e primary outcome was clinical improvement in NEWS2 changes. Duration of hospital stay, mortality rate, and safety profile of therapeutic regimens were secondary outcomes.Results: Between March 20 and April 3, 2020, a total of 114 patients were recruited and 59 patients completed the study. The IFN group had a significant improvement in clinical symptoms due to a significant reduction in NEWS2 (83.3% (25) vs 48.3% (14), P= 0.004). The time to clinical response in the IFN group was shorter than the control group (7 (5-12) days vs 9.5 (7-18), P=0.037). The IFN group also showed a significantly lower rate of 28-day mortality (6.8% (2) vs 34.5% (10), P= 0.01) and a lower need for invasive ventilation (6.8% (2) vs 34.5 (10), P= 0.008). Although the duration of ICU stay was marginally shorter in the IFN group, the results were not significantly different between the two groups (P=0.06).Conclusion: IFN beta-1b could be a potential therapeutic option for patients with moderate to severe COVID-19. 
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله | Nima Rouhani
Department of Infectious Diseases, Ibne Sina Medical and Educational Center, Mazandaran University of Medical Sciences, Sari, Iran.


| Elahe Karimpour-razkenari
Department of Clinical Pharmacy, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.


| Mostafa Alizadeh Forutan
Department of Internal Medicine, Ibne Sina Medical and Educational Center, Mazandaran University of Medical Sciences, Sari, Iran.


| Monireh Ghazaeian
Department of Infectious Diseases, Ibne Sina Medical and Educational Center, Mazandaran University of Medical Sciences, Sari, Iran AND Pharmaceutical Research Center, Mazandaran University of Medical Sciences, Sari, Iran.


| Ebrahim Salehifar
Department of Infectious Diseases, Ibne Sina Medical and Educational Center, Mazandaran University of Medical Sciences, Sari, Iran AND Pharmaceutical Research Center, Mazandaran University of Medical Sciences, Sari, Iran.


| Mohammad Sadegh Rezai
Pediatric Infectious Diseases Research Center, Mazandaran University of Medical Sciences, Sari, Iran.


| Sahar Fallah
Department of Biostatistic, Ibne Sina Medical and Educational Center, Mazandaran University of Medical Sciences, Sari, Iran.
نشانی اینترنتی https://jpc.tums.ac.ir/index.php/jpc/article/view/423
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات